Insights

Strategic considerations - why opt-out or why not?

von Dr. Anja Lunze, LL.M.

Pharmaceutical trade mark confusion

Using intellectual property protection

von Colin McCall

EU Commission regulates post-authorisation efficacy studies ("PAES")

von Dr. Wolfgang Rehmann

Personalised medicine – challenges of authorisation and reimbursement

von Dr. Manja Epping

There is more than one way to extend data exclusivity periods

von Edward Vickers

Companion diagnostics: legislation in progress

von Dr. Manja Epping

What the new Customs Regulation means in practice

von Roland Mallinson

Paediatric extensions to SPCs

von Edward Vickers